Lupin Unveils Strategic Partnership Program for Long-Acting Injectable Platform

Global pharma major Lupin Limited has announced the launch of a strategic partnership program for its long-acting injectable (LAI) platform, PrecisionSphere™, developed by its subsidiary, Nanomi B.V. The platform, which has received U.S. FDA approval, aims to expand patient access to advanced LAI treatments through new global strategic collaborations. The partnership program is designed to foster collaborations with companies looking to extend their product lifecycles, especially those that could benefit from longer-acting formulations. PrecisionSphere™ addresses key compliance issues and enables optimized drug levels, leading to improved injectability and potentially better treatment outcomes for patients.